Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control

Not Applicable

Completed

Conditions: Newly Diagnosed Type 2 Diabetes
Prediabetes

Interventions: Dietary Supplement: placebo
Dietary Supplement: jerusalem artichoke and fermented soybeans powder mixture

First Posted Date: 2015-07-23

Last Posted Date: 2015-07-23

Lead Sponsor: Yonsei University

Target Recruit Count: 60

Registration Number: NCT02506582

Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection

Not Applicable

Completed

Conditions: Early Gastric Cancer
Gastric Adenoma

Interventions: Drug: midazolam 0.02mg/kg
Drug: No premedication

First Posted Date: 2015-07-21

Last Posted Date: 2016-03-07

Lead Sponsor: Yonsei University

Target Recruit Count: 72

Registration Number: NCT02504164

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul, Korea, Republic of

A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation

Phase 4

Completed

Conditions: End Stage Liver Disease

Interventions: Drug: Propofol total intravenous anesthesia
Drug: Desflurane balanced anesthesia

First Posted Date: 2015-07-21

Last Posted Date: 2017-07-05

Lead Sponsor: Yonsei University

Target Recruit Count: 136

Registration Number: NCT02504138

Locations: 🇰🇷
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation

Not Applicable

Conditions: Atrial Fibrillation

Interventions: Drug: novel oral anticoagulant for 30 days
Drug: novel oral anticoagulant for 24 hour

First Posted Date: 2015-07-21

Last Posted Date: 2019-02-15

Lead Sponsor: Yonsei University

Target Recruit Count: 433

Registration Number: NCT02504177

Locations: 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy

Phase 2

Conditions: Melanoma

Interventions: Drug: regorafenib

First Posted Date: 2015-07-17

Last Posted Date: 2021-04-05

Lead Sponsor: Yonsei University

Target Recruit Count: 36

Registration Number: NCT02501551

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastroesophageal Junction Cancer
Gastric Cancer

Interventions: Drug: afatinib
Drug: paclitaxel

First Posted Date: 2015-07-17

Last Posted Date: 2023-01-27

Lead Sponsor: Yonsei University

Target Recruit Count: 72

Registration Number: NCT02501603

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul, Korea, Republic of

Optimal Dose of Combination of Rocuronium and Cisatracurium

Not Applicable

Completed

Conditions: Anesthesia
Chronic Otitis Media

Interventions: Drug: 10% reduction of combination of Esmeron® and Nimbex®
Drug: 20% reduction of combination of Esmeron® and Nimbex®

First Posted Date: 2015-07-13

Last Posted Date: 2018-03-02

Lead Sponsor: Yonsei University

Target Recruit Count: 81

Registration Number: NCT02495038

A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)

Phase 2

Completed

Conditions: Fibromatosis

Interventions: Drug: Imatinib

First Posted Date: 2015-07-13

Last Posted Date: 2020-01-14

Lead Sponsor: Yonsei University

Target Recruit Count: 21

Registration Number: NCT02495519

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Gastric Adenocarcinoma

Interventions: Drug: Induction DCS chemotherapy

First Posted Date: 2015-07-13

Last Posted Date: 2020-01-14

Lead Sponsor: Yonsei University

Target Recruit Count: 42

Registration Number: NCT02495493

Locations: 🇰🇷
Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul, Korea, Republic of

Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)

Phase 4

Conditions: Acute Coronary Syndrome

Interventions: Drug: Ticagrelor monotherapy
Drug: Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)

First Posted Date: 2015-07-10

Last Posted Date: 2018-06-20

Lead Sponsor: Yonsei University

Target Recruit Count: 3056

Registration Number: NCT02494895

Locations: 🇰🇷
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy